ABCA3 lung disease in an ex 27 week preterm infant responsive to systemic glucocorticosteroids

Area of Science:

• Neonatal respiratory medicine
• Genetic disorders
• Pulmonary surfactant metabolism

Background:

• Infantile respiratory distress can stem from various causes, including genetic mutations affecting lung function.
• The ATP-binding cassette transporter A3 (ABCA3) plays a crucial role in surfactant lipid transport within alveolar type II cells.

Observation:

• A premature infant (28 weeks gestation) presented with persistent diffuse lung disease unresponsive to standard prematurity care.
• Genetic analysis revealed homozygosity for a missense mutation in the ABCA3 gene.
• Clinical course and imaging suggested a primary diffuse lung disease of infancy rather than chronic lung disease of prematurity.

Findings:

• The infant's severe lung disease demonstrated a remarkable response to systemic corticosteroid therapy.
• This case highlights the potential therapeutic benefit of glucocorticosteroids in ABCA3-related lung disease.

Implications:

• Systemic corticosteroids may be a viable treatment option for infants with ABCA3 gene mutations and diffuse lung disease.
• Further research into the mechanisms of ABCA3 function and its response to anti-inflammatory agents is warranted.
• This case expands the understanding of therapeutic strategies for rare genetic pulmonary disorders in neonates.